Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 2Neoplasms 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 5Gemcitabine 4Albumin-Bound Paclitaxel 4Trastuzumab 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3pazopanib 2Taxes 2Sorafenib 2Radiotherapy 2Radiation 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Doxorubicin 2Docetaxel 2Capecitabine 2romidepsin 1rV-Tricom 1peginterferon alfa-2a 1pegfilgrastim 1oblimersen 1methyl N-acetylsibirosaminide 1ixabepilone 1fludarabine phosphate 1fludarabine 1exemestane 1cediranib 1alvocidib 1Zoledronic Acid 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms, Male × Tomography, Emission-Computed × Clear all
NCT01931709 2023-11-18

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

University of Washington

Phase NA Terminated
35 enrolled 11 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡